Brainsway Deep TMS Therapy - for Brain Disorder Treatment

A double-blind study to explore the safety and efficacy of deep transcranial magnetic stimulation (Deep TMS) of the parietal cortex using the HMCIPCC coil in the treatment of patients with amnestic mild cognitive impairment (aMCI)

Advanced Mental Health Care, Juno Beach, Florida, USA

20 February 2014

Since the parietal cortex of MCI patient’s exhibits neurodegeneration and reduced activity, the current study will explore the potential beneficial effects of excitatory (10 Hz) parietal Brainsway® Deep TMS on the symptoms of MCI. The trial schedule for each subject will include 8 weeks of tri-weekly treatment. Additionally, an evaluation will be conducted one year after the end of treatment.

The rationale for the choice of these stimulation parameters is based on previous studies utilizing Deep TMS for the treatment of major depression, which demonstrated the efficacy (as measured by depression and cognitive scales) of high-frequency stimulation applied over the prefrontal cortex. Further justification for this choice was obtained from the results of the second safety study conducted with the H-coils and the results of the depression clinical trials at the Shalvata Hospital (without drug therapy) and at the Hadassah Ein Kerem Hospital (in conjunction with drug therapy).

Furthermore, TMS studies performed with Alzheimer’s patients indicate a greater sensitivity of these patients to stimulation. This finding was taken into consideration when selecting the stimulation parameters for the current study’s protocol, even though the current study involves MCI patients rather than AD patients.

Contact: Aron Tendler, MD  tel:561-333-8884 email: aron.tendler@gmail.com

Principal Investigator: Aron Tendler, MD


© Brainsway Ltd.® 2014 | All rights reserved. Patients Portal · Brainsway Deep TMS · FDA Clearance · Disclaimer · Privacy Policy · Terms of Use